These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 33291334)

  • 21. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β-lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D).
    Romero E; Oueslati S; Benchekroun M; D'Hollander ACA; Ventre S; Vijayakumar K; Minard C; Exilie C; Tlili L; Retailleau P; Zavala A; Elisée E; Selwa E; Nguyen LA; Pruvost A; Naas T; Iorga BI; Dodd RH; Cariou K
    Eur J Med Chem; 2021 Jul; 219():113418. PubMed ID: 33862516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
    Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii.
    Vázquez-Ucha JC; Maneiro M; Martínez-Guitián M; Buynak J; Bethel CR; Bonomo RA; Bou G; Poza M; González-Bello C; Beceiro A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel metallo-β-lactamases inhibitors restore the susceptibility of carbapenems to New Delhi metallo-lactamase-1 (NDM-1)-harbouring bacteria.
    Guo Y; Liu H; Yang M; Ding R; Gao Y; Niu X; Deng X; Wang J; Feng H; Qiu J
    Br J Pharmacol; 2024 Jan; 181(1):54-69. PubMed ID: 37539785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4-(
    Gavara L; Verdirosa F; Legru A; Mercuri PS; Nauton L; Sevaille L; Feller G; Berthomieu D; Sannio F; Marcoccia F; Tanfoni S; De Luca F; Gresh N; Galleni M; Docquier JD; Hernandez JF
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32717907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New promising β-lactamase inhibitors for clinical use.
    Olsen I
    Eur J Clin Microbiol Infect Dis; 2015 Jul; 34(7):1303-8. PubMed ID: 25864193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ZN148 Is a Modular Synthetic Metallo-β-Lactamase Inhibitor That Reverses Carbapenem Resistance in Gram-Negative Pathogens
    Samuelsen Ø; Åstrand OAH; Fröhlich C; Heikal A; Skagseth S; Carlsen TJO; Leiros HS; Bayer A; Schnaars C; Kildahl-Andersen G; Lauksund S; Finke S; Huber S; Gjøen T; Andresen AMS; Økstad OA; Rongved P
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Repurposing of the Unithiol: Inhibition of Metallo-β-Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections.
    Grigorenko VG; Khrenova MG; Andreeva IP; Rubtsova MY; Lev AI; Novikova TS; Detusheva EV; Fursova NK; Dyatlov IA; Egorov AM
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
    Liu B; Trout REL; Chu GH; McGarry D; Jackson RW; Hamrick JC; Daigle DM; Cusick SM; Pozzi C; De Luca F; Benvenuti M; Mangani S; Docquier JD; Weiss WJ; Pevear DC; Xerri L; Burns CJ
    J Med Chem; 2020 Mar; 63(6):2789-2801. PubMed ID: 31765155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Faropenem reacts with serine and metallo-β-lactamases to give multiple products.
    Lucic A; Hinchliffe P; Malla TR; Tooke CL; Brem J; Calvopiña K; Lohans CT; Rabe P; McDonough MA; Armistead T; Orville AM; Spencer J; Schofield CJ
    Eur J Med Chem; 2021 Apr; 215():113257. PubMed ID: 33618159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten Years with New Delhi Metallo-β-lactamase-1 (NDM-1): From Structural Insights to Inhibitor Design.
    Linciano P; Cendron L; Gianquinto E; Spyrakis F; Tondi D
    ACS Infect Dis; 2019 Jan; 5(1):9-34. PubMed ID: 30421910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
    García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
    Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro potentiation of carbapenems with tannic acid against carbapenemase-producing enterobacteriaceae: exploring natural products as potential carbapenemase inhibitors.
    Somboro AM; Osei Sekyere J; Amoako DG; Kumalo HM; Khan R; Bester LA; Essack SY
    J Appl Microbiol; 2019 Feb; 126(2):452-467. PubMed ID: 30365206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge.
    Nordmann P
    Med Mal Infect; 2014 Feb; 44(2):51-6. PubMed ID: 24360201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbapenemases in Enterobacteriaceae: types and molecular epidemiology.
    Martínez-Martínez L; González-López JJ
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():4-9. PubMed ID: 25542046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acinetobacter baumannii: biology and drug resistance - role of carbapenemases.
    Nowak P; Paluchowska P
    Folia Histochem Cytobiol; 2016; 54(2):61-74. PubMed ID: 27270503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the development of β-lactamase inhibitors.
    Jalde SS; Choi HK
    J Microbiol; 2020 Aug; 58(8):633-647. PubMed ID: 32720096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical Activity of Vaborbactam.
    Tsivkovski R; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.